Business Context and Reporting Period
Company: Nanophase Technologies Corporation (Note: Metadata listed "SOLESENCE, INC." but filing text confirms Nanophase Technologies Corporation).
Reporting Period: Quarterly Report (Form 10-Q) for the period ended September 30, 2000.
Business Overview: The Company develops and sells nanocrystalline materials for commercial production. Revenue is generated through product sales, development arrangements, and technology licensing. Major markets include healthcare, electronics, and catalysts.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2000 | Nine Months Ended Sep 30, 2000 |
|---|---|---|
| Total Revenue | $1,354,951 | $3,079,208 |
| Net Loss | $(715,241) | $(3,402,569) |
| Net Loss Per Share | $(0.05) | $(0.26) |
| Cash and Cash Equivalents | $412,643 (Sep 30, 2000) | N/A |
| Investments | $18,213,349 (Sep 30, 2000) | N/A |
| Total Current Assets | $21,259,608 | N/A |
| Total Current Liabilities | $1,890,625 | N/A |
| Accumulated Deficit | $(27,898,187) | N/A |
Cash Flow (Nine Months Ended Sep 30, 2000):
- Net cash used in operating activities: $(3,642,281)
- Net cash provided by investing activities: $2,152,554
- Net cash provided by financing activities: $1,277,861
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased significantly compared to the prior year. For the nine months ended September 30, 2000, revenue was $3,079,208 versus $1,019,416 in 1999. Product revenue drove this increase, rising to $2,739,939 from $862,499.
- Cost of Revenue: Increased to $3,475,960 (nine months 2000) from $2,058,982 (nine months 1999), attributed to higher product sales volume. However, cost of revenue as a percentage of total revenue decreased.
- Operating Expenses:
- R&D: Increased to $1,431,474 (nine months 2000) from $1,129,009 (nine months 1999) due to new research personnel.
- Selling, General & Administrative (SG&A): Decreased to $2,466,307 (nine months 2000) from $3,138,154 (nine months 1999), primarily due to reduced legal expenses and the absence of non-recurring restructuring costs present in 1999.
- Net Loss: Net loss improved to $(3,402,569) for the nine months ended September 30, 2000, compared to $(4,444,947) in the same period in 1999.
Guidance, Outlook, Risks, and Contingencies
Liquidity and Capital Resources: The Company holds approximately $18.6 million in cash, cash equivalents, and investments. Management believes current resources and interest income are adequate to fund current operating plans. However, future capital requirements may necessitate additional financing, which could be dilutive.
Legal Proceedings (Contingencies):
- Consolidated Complaint (1933 Act): The Company reached an oral agreement in principle to settle claims for $4,025,000. The settlement is expected to be funded by directors and officers liability insurance and is not considered a material adverse effect. Final approval by the Court is pending.
- Preferred Stockholders' Complaint (1934 Act): A separate class action regarding the IPO remains pending. The Court denied a motion to dismiss in August 2000. The Company intends to defend vigorously but cannot predict the outcome or potential financial impact.
Risks: Key risks include uncertain demand for nanocrystalline materials, dependence on a limited number of key customers, limited manufacturing capacity, and the resolution of ongoing litigation.
Tax Attributes: The Company has a net operating loss carryforward of approximately $28 million, subject to limitations due to potential ownership changes. A foreign tax credit carryforward of $156,000 expires in 2013 if unused.
Investor Verification Checklist
- Verify the status of the $4,025,000 settlement agreement regarding the 1933 Act litigation and confirm insurance coverage details.
- Monitor the progress of the pending 1934 Act preferred stockholders' complaint and potential exposure.
- Assess the sustainability of revenue growth given the Company's dependence on a limited number of key customers.
- Review the Company's ability to maintain liquidity without dilutive equity financing as R&D and manufacturing expansion continue.
- Confirm the utilization timeline for the $28 million net operating loss carryforward given potential IRS ownership change limitations.